• About
    • Company Profile
    • Company Introduction
    • R&D
      • Core Technology
      • PTS: Functional Mechanism
      • R&D Center
      • Paper Publish
    • History
    • Our Team
    • Partnership
      • Partnerships – Human Indication
      • Partnerships – Animal Drugs
  • News
    • Coming event
    • News Focus
    • Activites section
    • Announcement
  • Products
    • Para-Toluenesulfonamide (PTS)
      • PTS: Functional Mechanism
      • Product Features
      • Comparison with existing cancer treatments
    • Market Position
    • R&D
      • PTS100
      • PTS500
      • PTS02
      • GWA103
      • GWA106
  • Clinical Trials
    • Product progress
    • Compassionate use
      • Compassionate use cases
  • Partnership
    • Partnerships – Human Indication
    • Partnerships – Animal Drugs
  • Animals
  • Medical
    • Cosmetics
      • MAGIC SKIN GEL
        • DM
    • ROAN
      • DM
    • Pet Gel-Speedling
  • Investors
    • Important news
      • 2026/9/24 To announce in accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
      • 2026/9/19 On behalf of Tianjin Chase Sun Jiandakang, PTS Phase II HCC trial abstract in China accepted for presentation at ESMO Asia 2026.
      • 2026/9/10 On behalf of subsidiary Tianjin Chase Sun Jiandakang, PTS-302 NDA was accepted for review in Morocco.
      • 2026/09/05 Gongwin Pet Biopharm: Pet anti-cancer drug Gwa103 passes MOA technical review for NDA.
      • 2026/8/25 In accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
      • 2026/8/25 Company's Board of Directors has approved the consolidated financial report for the Second quarter of year 2026
    • Financial area
      • Annual Report
      • Monthly Revenue
        • 2026
        • 2025
        • 2024
      • Consolidated Financial Reports
    • Shareholders area
    • Corporate Governance
  • Contact

下載產品DM

  • LINKEDIN
  • YOUTUBE
  • 中文
  • EN

INQUIRY

()
  • 中文
  • EN

下載產品DM

SCROLL DOWN

  • Home
  • News
  • Announcement
  • Ablative therapy for equine cutaneous tumors
News
  • Coming event
    • HUMAN
    • PETS
  • News Focus
    • Gongwin-KY Invited by EIEV in the UAE to Explore PTS Applications in Equine Oncology
    • Breakthrough in Pet Cancer Treatment: Gongwin's Novel Canine Melanoma Drug Clears Key Regulatory Milestone
    • Gongwin-KY's Liver Cancer Therapy Published in International Journal; Phase III Clinical Trial Planned
    • New Anti-Cancer Weapon Secures U.S. Patent as Gongwin Eyes Global Licensing
  • Activites section
    • Emirates International Endurance Village(EIEV) in Abu Dhabi, UAE
    • TSIR 2026 with Veterinarians
    • 2026 13th Veterinary Conference of the Chinese Veterinary Medical Association
    • 20206 APSCVIR
  • Announcement
    • PTS Injection for Recurrent Hepatocellular Carcinoma Adjacent to the Heart: A Case Report
    • Clinical outcomes of PTS treatment in equine melanoma
    • Ablative therapy for equine cutaneous tumors
    • WEVA 2026 Thailand article
    • ASCO-Publication article
    • Gongwin Biopharm Expands an new PTS Ablation Approach for Lung Cancer Across Southeast Asia

Ablative therapy for equine cutaneous tumors

 

Publication 

Intratumoral para-toluenesulfonamide as a tumor-ablative therapy for equine cutaneous tumors: a case series of three horses

Publication link   ScienceDirect

 

 

 

 

Previous page
Back to list
Next page

TOP

Please enter a product name
  • LINKEDIN
  • YOUTUBE
Gongwin Biopharm Co., Ltd.
TEL +886-2-2503-5282
MAIL info@gongwinbiopharm.com
ADDRESS 3F, No. 80, Sec. 1, Jianguo N. Rd., Zhongshan Dist., Taipei City 10491, Taiwan
  • LINKEDIN
  • YOUTUBE
© 2026 Gongwin Biopharm Co., Ltd. All rights reserved. Designed By  Winho
Privacy policy  |  Sitemap